3-June-2019: The global vaginitis therapeutics market size is
expected to reach USD 4.21 billion by 2025, according to a new report by Grand
View Research, Inc. It is estimated to expand at a CAGR of 8.4% during the
forecast period. Supportive initiatives by government and non-government
agencies to increase awareness level among women is driving the demand for
vaginitis drugs. Increased consumption of alcohol is also estimated to fuel the
adoption of these drugs. Around 5.3 million women in the U.S. are at risk related
to health and general well-being.
Furthermore, rising R&D
activities for vaginitis therapeutics is anticipated to accelerate the market
growth. National Institute of Allergy and Infectious Diseases (NIAID)-funded
research has discovered various important data about yeast generative behavior,
which could result in new way of treatment for yeast infections. In addition,
introduction of new drugs by key companies is expected to propel the market
growth. For instance, in September 2017, Symbiomix Therapeutics received FDA
approval for Solosec (secnidazole) for the treatment of bacterial vaginosis.
In
depth research report on Vaginitis Therapeutics Market
Further
key findings from the study suggest:
· Anti-bacterial
segment led the market in 2017 owing to the availability of a wide product
range and higher number of cases of bacterial vaginosis disease
· Hormone
is expected to witness lucrative growth with a CAGR of 9.1% over the forecast
period due to the presence of pipeline products and rising adoption of products
· Prescription
type held the largest market share in 2017, in terms of revenue. The segment
was valued at USD 1.14 billion owing to the higher efficacy and safety of
prescribed drugs and availability of a wide range of drugs for severe and
recurring vaginitis
· Over
the counter is expected to be the fastest-growing type in the coming years with
a CAGR of 8.7% due to increasing number of FDA approvals for the treatment of
mild vaginitis
· North
America is estimated to be the largest regional market. It was the dominant
region in 2017, in terms of revenue, owing to of high-quality healthcare
services and increasing cases of vaginitis
· Asia
Pacific is expected to be the fastest-growing region registering a lucrative
CAGR over the forecast period. This growth is attributed to favorable
government initiatives and rising disposable income along with the presence of
a large target population base.
· Key
players in the vaginitis therapeutics market are Pfizer, Inc.; Merck & Co.;
Novartis AG; Bayer AG; Lupin Pharmaceuticals, Inc.; Symbiomix Therapeutics,
Inc.; and Mission Pharmacal Company
· Most of
these companies focus on strategic initiatives, such as collaborations,
M&A, and product portfolio expansion. For instance, in October 2017, Lupin
Pharmaceuticals acquired Symbiomix Therapeutics to expand its product
portfolio.
Grand View Research has
segmented the global vaginitis therapeutics market on the basis of product,
type, and region:
Vaginitis
Therapeutics Product Outlook (Revenue, USD Million, 2014 - 2025)
· Anti-fungal
· Anti-bacterial
· Hormone
Vaginitis
Therapeutics Type Outlook (Revenue, USD Million, 2014 - 2025)
· Over-The-Counter
(OTC)
· Prescription
(Rx)
Browse
more research reports of this category:
About
Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, the company offers market
intelligence studies ensuring relevant and fact-based research across a range
of industries including technology, chemicals, materials, healthcare and
energy.
No comments:
Post a Comment